Relationship between clinical and pathologic findings in patients with chronic liver diseases

World Journal of Gastroenterology

Volumn 9, Issue 12, 2003, Pages 2796-2800

  Lu, Lun Gen ^a   Zeng, Min De ^a   Mao, Yi Min ^a   Li, Ji Qiang ^a   Qiu, De Kai ^a   Fang, Jing Yuan ^a   Cao, Ai Ping ^a   Wan, Mo Bin ^b   Li, Cheng Zhong ^b   Ye, Jun ^c   Cai, Xiong ^d   Chen, Cheng Wei ^e   Wang, Ji Yao ^f   Wu, Shan Ming ^g   Zhu, Jin Shui ^h   Zhou, Xia Qiu ⁱ  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Shanghai Putuo District Central Hospital   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e Nanjing Military Command   (China)

^f ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^g Shanghai Institute of Infectious Disease and Biosecurity   (China)

^h Shanghai No 6 People's Hospital   (China)

ⁱ SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 2 MACROGLOBULIN; APOPROTEIN; ASPARTATE AMINOTRANSFERASE; BIOCHEMICAL MARKER; GLOBULIN; HYALURONIC ACID; PEPTIDE DERIVATIVE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADOLESCENT; ADULT; AGE; ARTICLE; CHINA; CHRONIC DISEASE; CHRONIC LIVER DISEASE; CLASSIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PROTHROMBIN TIME; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STAGING; SYMPTOM; THROMBOCYTE;

EID: 9144223374     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i12.2796     Document Type: Article

References (40)

1. Albanis E, Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 2001; 5: 315-334
2. Brenner DA, Waterboer T, Choi SK, Lindquist JN, Stefanovic B, Burchardt E, Yamauchi M, Gillan A, Rippe RA. New aspects of hepatic fibrosis. J Hepatol 2000; 32(1Suppl1): 32-38
3. Albanis E, Safadi R, Friedman SL. Treatment of hepatic fibrosis: Almost there. Curr Gastroenterol Rep 2003; 5: 48-56
4. Rockey DC. The cell and molecular biology of hepatic fibrogenesis. Clinical and therapeutic implications. Clin Liver Dis 2000; 4: 319-355
5. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: New insights and prospects for therapy. J Gastroenterol Hepatol 1999; 14: 618-633
6. Friedman SL. Molecular mechanisms of hepatic fibrosis and principles of therapy. J Gastroenterol 1997; 32: 424-430
7. Musca A, Paoletti V, De Matteis A, Mammarella A, Labbadia G, Grassi M, Paradiso M. Liver fibrosis: What's the beginning of autonomic deficit? Scand J Gastroenterol 2002; 37: 1235-1236
8. Dai WJ, Jiang HC. Advances in gene therapy of liver cirrhosis: A review. World J Gastroenterol 2001; 7: 1-8
9. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, Gallois Y, Rifflet H, Maiga MY, Penneau-Fontbonne D, Cales P. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113: 1609-1616
10. Tsutsumi M, Takase S, Urashima S, Ueshima Y, Kawahara H, Takada A. Serum markers for hepatic fibrosis in alcoholic liver disease: Which is the best marker, type III procollagen, type IV collagen, laminin, tissue inhibitor of metalloproteinase, or prolyl hydroxylase? Alcohol Clin Exp Res 1996; 20: 1512-1517
11. Aube C, Oberti F, Korali N, Namour MA, Loisel D, Tanguy JY, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Rifflet H, Maiga MY, Penneau-Fontbonne D, Caron C, Cales P. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 1999; 30: 472-478
12. Zaitoun AM, Al Mardini H, Awad S, Ukabam S, Makadisi S, Record CO. Quantitative assessment of fibrosis and steatosis in liver biopsies from patients with chronic hepatitis C. J Clin Pathol 2001; 54: 461-465
13. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36(5 Suppl 1): S57-S64
14. Thabut D, Simon M, Myers RP, Messous D, Thibault V, Imbert-Bismut F, Poynard T. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 2003; 37: 1220-1221
15. Tran A, Hastier P, Barjoan EM, Demuth N, Pradier C, Saint-Paul MC, Guzman-Granier E, Chevallier P, Tran C, Longo F, Schneider S, Piche T, Hebuterne X, Benzaken S, Rampal P. Noninvasive prediction of severe fibrosis in patients with alcoholic liver disease. Gastroenterol Clin Biol 2000; 24: 626-630
16. Prevention and treatment projects of virus hepatitis (tryout). Zhonghua Neike Zazhi 1995; 34: 788-791
17. Stickel F, Urbaschek R, Schuppan D, Poeschl G, Oesterling C, Conradt C, McCuskey RS, Simanowski UA, Seitz HK. Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease. Dig Dis Sci 2001; 46: 2025-2032
18. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42: 558-563
19. Murawaki Y, Ikuta Y, Okamoto K, Koda M, Kawasaki H. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J Gastroenterol 2001; 36: 399-406
20. Pares A, Deulofeu R, Gimenez A, Caballeria L, Bruguera M, Caballeria J, Ballesta AM, Rodes J. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996; 24: 1399-1403
21. Zheng M, Cai WM, Weng HL, Liu RH. ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis. World J Gastroenterol 2002; 8: 1073-1076
22. Zheng M, Cai W, Weng H, Liu R. Determination of serum fibrosis indexes in patients with chronic hepatitis and its significance. Chin Med J 2003; 116: 346-349
23. Shahin M, Schuppan D, Waldherr R, Risteli J, Risteli L, Savolainen ER, Oesterling C, Abdel Rahman HM, El Sahly AM, Abdel Razek SM. Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease. Hepatologl 1992; 15: 637-644
24. Ramadori G, Zohrens G, Manns M, Rieder H, Dienes HP, Hess G, Meyer KH, Buschenfelde Z. Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity. Eur J Clin Invest 1991; 21: 323-330
25. Hirayama C, Suzuki H, Tanaka A, Fujisawa K, Tanikawa K, Igarashi S. Serum type IV collagen in various liver diseases in comparison with serum 7S collagen, laminin, and type III procollagen peptide. J Gastroenterol 1996; 31: 242-248
26. Fabris C, Falleti E, Federico E, Toniutto P, Pirisi M. A comparison of four serum markers of fibrosis in the diagnosis of cirrhosis. Ann Clin Biochem 1997; 34(Pt 2): 151-155
27. Walsh KM, Fletcher A, MacSween RN, Morris AJ. Comparison of assays for N-amino terminal propeptide of type III procollagen in chronic hepatitis C by using receiver operating characteristic analysis. Eur J Gastroenterol Hepatol 1999; 11: 827-831
28. Castera L, Hartmann DJ, Chapel F, Guettier C, Mall F, Lons T, Richardet JP, Grimbert S, Morassi O, Beaugrand M, Trinchet JC. Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. J Hepatol 2000; 32: 412-418
29. Lin DY, Chu CM, Sheen IS, Liaw YF. Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases. Dig Dis Sci 1995; 40: 21-27
30. Myers RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T. Biochemical markers of fibrosis in patients with chronic hepatitis C: A comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci 2003; 48: 146-153
31. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001; 357: 1069-1075
32. Naveau S, Montembault S, Balian A, Giraud V, Aubert A, Abella A, Capron F, Chaput JC. Biological diagnosis of the type of liver disease in alcoholic patients with abnormal liver function tests. Gastroenterol Clin Biol 1999; 23: 1215-1224
33. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T. Biochemical markers of liver fibrosis: A comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 2419-2425
34. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, Maiga MY, Gallois Y, Cales P. Histopathological evaluation of liver fibrosis: Quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998; 28: 439-446
35. Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci 1994; 39: 2426-2432
36. Jiang JJ, Salvucci M, Thepot V, Pol S, Ekindjian OG, Nalpas B. PGA score in diagnosis of alcoholic fibrosis. Lancet 1994; 343: 803
37. Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP, Murray-Lyon IM, Peters TJ, Williams R, Thompson RP. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993; 342: 895-898
38. Croquet V, Vuillemin E, Ternisien C, Pilette C, Oberti F, Gallois Y, Trossaert M, Rousselet MC, Chappard D, Cales P. Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol 2002; 14: 1133-1141
39. Cadranel JF, Mathurin P. Prothrombin index decrease: A useful and reliable marker of extensive fibrosis? Eur J Gastroenterol Hepatol 2002; 14: 1057-1059
40. Lu LG, Zeng MD, Wan MB, Li CZ, Mao YM, Li JQ, Qiu DK, Cao AP, Ye J, Cai X, Chen CW, Wang JY, Wu SM, Zhu JS, Zhou XQ. Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. World J Gastroenterol 2003; 9: 2574-2578